Re: Adverse events associated with testosterone administration

European Urology

Volumn 59, Issue 3, 2011, Pages 465-

  Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TESTOSTERONE;

ANDROGEN THERAPY; CANCER RISK; CARDIOVASCULAR RISK; HEART INFARCTION; HUMAN; NOTE; PATIENT ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SYNCOPE;

EID: 79551495652     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.12.027     Document Type: Note

References (4)

1. A. Morgentaler Testosterone and prostate cancer: an historical perspective on a modern myth Eur Urol 50 2006 935 939
2. A. Morgentaler, and A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the Saturation Model and the limits of androgen-dependent growth Eur Urol 55 2009 310 321
3. U. Srinivas-Shankar, S.A. Roberts, and M.J. Connolly Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study J Clin Endocrinol Metab 95 2010 639 650
4. C.J. Malkin, P.J. Pugh, P.D. Morris, S. Asif, T.H. Jones, and K.S. Channer Low serum testosterone and increased mortality in men with coronary heart disease Heart 96 2010 1821 1825